Skip to main content
. 2005 Apr 26;92(9):1621–1625. doi: 10.1038/sj.bjc.6602579

Table 2. Objective tumour response rates.

  Anastrazole 1 mg Exemestane 25 mg
Response n=100 (%) n=50 (%)
CR 8 (8%) 1 (2%)
PR 19 (19%) 3 (6%)
Objective response rate 27 (27%) 4 (8%)
SD⩾24 weeks 46 (46%) 18 (36%)
Clinical benefit (CR+PR+SD⩾24 weeks) 73 (73%) 22 (44%)
SD<24 weeks 5 (5%) 7 (14%)
Progression 19 (19%) 20 (40%)